Therapeutic Asset Ratings

176 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fludarabine Cortical Thymoma	Beijing Biotech	P1/2	CC (47)
Fludarabine Unresectable Locally Advanced	Beijing Biotech	P1/2	CC (47)
Fludarabine Unresectable Locally Advanced or Metastatic Disease	Beijing Biotech	P1/2	CC (47)
Fludarabine Liver Cancer	Beijing Biotech	P1/2	CC (46)
Autologous Bcma/Cd19 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd19 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd19 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)

Showing 101 to 125 of 176 assets

PreviousPage 5 of 8Next